Table 1.
Clinical trials assessing recurrence-free survival after BCG treatment.
| Author, Year | n | BCG Dose | BCG Schedule | 1-Year Recurrence Events/Patients or % | Relative Risk of 1-Year Recurrence |
|---|---|---|---|---|---|
| Lamm, 1985 [86] | 60 | 120 mg intravesical Pasteur + 5 mg percutaneous | Weekly × 6 weeks | 3/6 BCG 4/6 no BCG |
0.75 |
| Pinsky, 1985 [87] | 88 | 120 mg intravesical Armand Frappier + 5 × 107 CFU percutaneous | Weekly × 6 weeks | 27/41 BCG 39/43 no BCG |
0.73 |
| Yamamoto, 1990 [88] | 44 | 80 mg Tokyo | Weekly × 6 weeks, every 2 weeks × 12 weeks, every month × 20 months | 4/20 BCG 13/20 no BCG |
0.31 |
| Pagano, 1991 [89] | 189 | 75 mg intravesical Pasteur | Weekly × 6 weeks, monthly × 1 year, then quarterly × 1 year | 6/43 BCG 31/39 no BCG |
0.18 |
| Melekos, 1990 [90] | 100 | 150 mg intravesical Pasteur | Weekly × 6 weeks, every 3 months × 2 years | 11/67 BCG 14/33 no BCG |
0.38 |
| Krege, 1996 [91] | 337 | 120 mg Connaught | Weekly × 6 weeks, monthly × 4 months | 28/98 BCG 43/116 no BCG |
0.78 |
| Herr, 2011 [97] | 816 | 50 mg TICE | Weekly × 6, no maintenance | 27% | - |
| Sfakianos, 2014 [98] | 1021 | 50 mg TICE | Weekly × 6, no maintenance | 28% | - |
| Matulay, 2021 [99] | 542 | 50 mg TICE | Weekly × ≥5 induction plus ≥2 maintenance | 8% | - |